Ropivacaine
- Generic Name
- Ropivacaine
- Brand Names
- Naropin
- Drug Type
- Small Molecule
- Chemical Formula
- C17H26N2O
- CAS Number
- 84057-95-4
- Unique Ingredient Identifier
- 7IO5LYA57N
- Background
Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
- Indication
Ropivacaine is indicated in adult patients for the induction of regional or local anesthesia for surgery or acute pain management.
- Associated Conditions
- Acute Pain, Postoperative pain
- Associated Therapies
- Surgical anesthesia therapy
Initial Topline Data for PRF-110 Phase 3 Clinical Trial Announced by PainReform
PainReform Ltd. announced partial topline data from its Phase 3 trial of PRF-110, showing statistically significant pain reduction over placebo in the first 48 hours post-bunionectomy surgery. However, data for the subsequent 24 hours is unclear, necessitating collaboration with Lotus Clinical Research to resolve issues. PRF-110, an extended-release ropivacaine formulation, aims to provide prolonged pain relief and reduce opioid use.
PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial
PainReform Ltd. announced partial Phase 3 data for PRF-110, showing significant pain reduction in the first 48 hours post-bunionectomy, but data for the subsequent 24 hours is unclear. The company is working with Lotus Clinical Research to resolve the issue.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath